



## DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

- POLICY:** Opioids – Fentanyl Transmucosal Products Drug Quantity Management Policy – Per Days
- Actiq® (fentanyl citrate oral transmucosal lozenge – Teva, generic) [brand discontinued]
  - Fentora® (fentanyl buccal tablet – Teva, generic) [discontinued]
  - Lazanda® (fentanyl nasal spray – West) [discontinued]
  - Subsys® (fentanyl sublingual spray – West) [discontinued]

**REVIEW DATE:** 05/02/2025

### INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## CIGNA NATIONAL FORMULARY COVERAGE:

### OVERVIEW

The transmucosal fentanyl drugs are indicated only for the management of **breakthrough pain in patients with cancer** who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain.<sup>1-4</sup>

Actiq (generic), Fentora (generic), and Subsys are immediate-release oral transmucosal formulations of fentanyl citrate.<sup>1-3</sup> Lazanda is a nasal spray intended for intranasal transmucosal administration.<sup>4</sup> The transmucosal fentanyl drugs are contraindicated in the management of acute or postoperative pain and in patients

with known intolerance or hypersensitivity to any components of the product. In addition, the transmucosal fentanyl drugs must not be used in patients who are not opioid tolerant (contraindicated). The products are approved for use only in the care of cancer patients and only by healthcare professionals (oncologists and pain specialists) who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.<sup>1-4</sup> Because of the risk of misuse, abuse, addiction, and overdose, these products are available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Transmucosal Immediate-Release Fentanyl (TIRF) REMS ACCESS program. Under the TIRF REMS ACCESS program, outpatients, prescribers who prescribe to outpatients, pharmacies, and distributors must enroll in the program.

Of note, all of the transmucosal fentanyl products have been discontinued by their manufacturers as of September 2024.<sup>5</sup>

## **Dosing**

### *Fentanyl Transmucosal Lozenges (Actiq, generic)*

The initial dose of fentanyl transmucosal lozenges for breakthrough cancer pain is 200 mcg.<sup>1</sup> Patients should only be prescribed an initial titration supply of six 200 mcg fentanyl transmucosal lozenges, and these should be used prior to increasing to a higher dose. Patients may re-dose one time within a single episode of breakthrough cancer pain, if needed. Re-dosing may start 15 minutes after the previous unit has been completed (30 minutes after the start of the previous lozenge). During the titration phase no more than two lozenges should be taken for each individual breakthrough cancer pain episode. A patient must wait  $\geq 4$  hours before treating another episode of breakthrough pain with fentanyl transmucosal lozenges. If treatment of several consecutive breakthrough cancer pain episodes requires more than one fentanyl transmucosal lozenge per episode, a dose increase to the next higher available strength should be considered. With each new dose of fentanyl transmucosal lozenges, the package labeling recommends that six units of the titration dose be prescribed. Each new dose of fentanyl transmucosal lozenges should be evaluated over several episodes of breakthrough cancer pain (generally 1 to 2 days) before adjusting the dose again. Once a successful dose has been found (i.e., an average episode is treated with a single lozenge), patients should limit consumption to four or fewer lozenges per day. Generally, the dose should be increased when the current dose fails to adequately treat the breakthrough pain episode for several consecutive episodes. If the patient experiences greater than four breakthrough pain episodes per day, then the dose of the long-acting opioid used for persistent cancer pain should be re-evaluated.

### *Fentanyl Buccal Tablets (Fentora, generic)*

In patients not currently taking another TIRF product, the initial dose of fentanyl buccal tablet is 100 mcg.<sup>2</sup> Dosing may be repeated one-time only during a single episode of breakthrough pain, if needed. Re-dosing may occur 30 minutes after the start of administration of the first dose and the same dosage strength should be used. A patient must wait  $\geq 4$  hours before treating another episode of breakthrough pain with fentanyl buccal tablet. Generally, the dose of fentanyl

buccal tablet should be increased when the patient requires more than one dose per breakthrough pain episode for several consecutive episodes. Titration should be initiated using 100 mcg tablets. Patients in need of > 100 mcg should use two 100 mcg tablets (one tablet on each side of the mouth). If this dose is not successful, two 100 mcg tablets may be placed on each side of the mouth (total of four 100 mcg tablets). For doses > 400 mg, titrate using multiples of 200 mcg. During titration, patients should only have one strength of Fentanyl buccal tablet available at any one time. Once a successful dose has been established, if the patient experiences greater than four breakthrough pain episodes per day, the dose of the maintenance opioid should be re-evaluated.

### *Subsys*

Due to differences in pharmacokinetic properties and individual variability, patients should not be switched on a mcg per mcg basis from any other fentanyl product to Subsys.<sup>3</sup> Product labeling contains dose conversion information for patients currently taking fentanyl transmucosal lozenge (Actiq, generic). If the patient is not currently taking fentanyl transmucosal lozenge (Actiq, generic), the initial dose of Subsys is 100 mcg. If adequate analgesia is obtained within 30 minutes of administration of the 100 mcg single spray, subsequent episodes of breakthrough pain should be treated with this dose. If adequate analgesia is not achieved after 30 minutes of the first 100 mcg dose, patients may take one additional dose of the same strength for that episode. The dose should be escalated in a step-wise manner over consecutive episodes of breakthrough pain until adequate analgesia with tolerable adverse effects is achieved. If there is a need to titrate to higher doses, the corresponding strength of sublingual spray should be prescribed (that is, 200 mcg, 400 mcg, 600 mcg, 800 mcg, OR two of the 600 mcg sprays [1,200 mcg] or two of the 800 mcg sprays [1,600 mcg]). Patients must wait ≥ 4 hours before treating another episode of breakthrough cancer pain with Subsys. Once titrated, Subsys should be administered as one spray under the tongue and dose consolidation should be utilized (e.g., if a patient's titrated dose is 200 mcg, the 200 mcg strength should be utilized instead of using two sprays of the 100 mcg strength). Patients may not use more than two sprays per episode of breakthrough cancer pain. The safety and efficacy of doses > 1,600 mcg or more than two sprays per episode have not been evaluated in clinical studies. There are no clinical data to support the use of a combination of dose strengths to treat an episode. It is advised that patients only have one strength of Subsys available at any time to reduce the risk of overdose. Use of Subsys should be limited to four or fewer doses per day once a successful dose is found. If more than four episodes of breakthrough pain are experienced per day, the dose of the long-acting opioid should be re-evaluated.

### *Lazanda*

Due to differences in pharmacokinetic properties and individual variability, patients should not be switched on a mcg per mcg basis from any other fentanyl product to Lazanda.<sup>4</sup> Lazanda must be primed prior to initial use. Treatment of all patients (including those switching from another fentanyl product) should begin with one 100 mcg spray of Lazanda (one spray in one nostril). If adequate analgesia is obtained within 30 minutes of administration of the 100 mcg single spray,

subsequent episodes of breakthrough pain should be treated with this dose. If adequate analgesia is not achieved with the first 100 mcg dose, the dose should be escalated in a stepwise manner to 200 mcg, 300 mcg, 400 mcg, 600 mcg and 800 mcg per dose over consecutive episodes of breakthrough pain until adequate analgesia with tolerable adverse effects is achieved. Lazanda should be administered as one spray in one nostril, one spray in each nostril, or up to two sprays per nostril (alternating each spray between nostrils). Patients must wait  $\geq 2$  hours before treating another episode of breakthrough cancer pain with Lazanda. The patient may require a different immediate-release medication for rescue during titration with inadequate pain relief. The safety and efficacy of doses  $> 800$  mcg (one 400 mcg spray in each nostril) have not been evaluated in clinical studies. There are no clinical data to support the use of a combination of dose strengths to treat an episode. If more than four episodes of breakthrough pain are experienced per day, the dose of the long-acting opioid should be re-evaluated. Lazanda should be limited to treating four or fewer episodes of breakthrough pain per day.

### **Availability**

Fentanyl transmucosal lozenges (Actiq, generic) are available in six dosage strengths: 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,200 mcg and 1,600 mcg.<sup>1</sup>

Fentanyl buccal tablets (Fentora, generic) are available in five dosage strengths: 100 mcg, 200 mcg, 400 mcg, 600 mcg, and 800 mcg.<sup>2</sup>

Subsys sublingual spray is available in seven dosage strengths: 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,200 mcg, and 1,600 mcg.<sup>3</sup> Each Subsys carton contains 30 individual blister packages containing single spray unit dose systems of Subsys. The 1,200 mcg and 1,600 mcg are supplied as two 600 mcg or two 800 mcg units in one package, respectively. After use, each unit dose system should be disposed of immediately.

Lazanda nasal spray is available in three dosage strengths: 100 mcg/100 mL and 400 mcg/100 mL mcg.<sup>4</sup> One spray contains 100 mL. Lazanda bottles contain 5.3 mL prior to priming and 5 mL or eight sprays after priming. Patients should dispose of a Lazanda bottle if they have used eight sprays, if it has been  $\geq 5$  days since the last time they used the bottle of Lazanda, or it has been  $\geq 14$  days since the bottle was primed.

### **POLICY STATEMENT**

This Drug Quantity Management program has been developed to promote dose consolidation, prevent stockpiling/waste, and address potential order entry error of transmucosal fentanyl products. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration, unless otherwise noted below. "One-time" approvals are provided for 1 year in duration.

### **Drug Quantity Limits**

The Express Scripts' initial quantity limit supplies a sufficient quantity for each of the transmucosal immediate-release fentanyl (TIRF) products to be utilized for up to **three** breakthrough pain episodes per day. The intent is for prescribers to maximize the long-acting pain medication that will control the chronic pain and minimize breakthrough pain episodes. Additional quantities, up to a maximum of **four** breakthrough pain episodes per day, are available through coverage review.

A quantity of **oral** transmucosal fentanyl products of 90 units (tablets [buccal], lozenges, and/or single spray units) will be covered per 30 days at retail or 270 units per 90 days at home delivery without prior authorization. Subsys sublingual spray is supplied in a carton containing 30 single spray units, therefore a quantity of 3 cartons is equal to 90 units and 9 cartons is equal to 270 units. A quantity of Lazanda nasal spray of 23 bottles (one bottle contains eight sprays after priming) will be covered per 30 days at retail at 69 bottles will be covered per 90 days at home delivery without prior authorization. These quantities are adequate for at least three episodes of breakthrough pain per day. For coverage of additional quantities, prior authorization is required. The quantity limit for the oral products and sublingual spray, is specific to the individual drugs or any combination of them.

### **Drug Quantity Limits**

<b>Product</b>	<b>Strength and Form</b>	<b>Retail Maximum Quantity per 30 Days</b>	<b>Home Delivery Maximum Quantity per 90 Days</b>
Actiq® (fentanyl citrate oral transmucosal lozenge, generic) [brand discontinued]	200 mcg lozenges	90 units	270 units
	400 mcg lozenges		
	600 mcg lozenges		
	800 mcg lozenges		
	1,200 mcg lozenges		
	1,600 mcg lozenges		
Fentora® (fentanyl buccal tablet, authorized generic) [discontinued]	100 mcg buccal tablets	90 units	270 units
	200 mcg buccal tablets		
	400 mcg buccal tablets		
	600 mcg buccal tablets		
	800 mcg buccal tablets		
Subsys® (fentanyl sublingual spray) [discontinued]	100 mcg spray units	90 units	270 units
	200 mcg spray units		
	400 mcg spray units		
	600 mcg spray units		
	800 mcg spray units		
	1,200 mcg spray units (packaged 2 x 600 mcg spray units in a single blister pack)*		
	1,600 mcg spray units (packaged as 2 x 800 mcg spray units in a single blister pack)*		
Lazanda® (fentanyl sublingual spray) [discontinued]	100 mcg/100 mL spray (8 sprays/5.3 mL bottle)	23 bottles	69 bottles

	400 mcg/100 mL spray (8 sprays/5.3 mL bottle)	23 bottles <sup>†</sup>	69 bottles
--	--	-------------------------	------------

\* 180 spray units is equivalent to 6 cartons of Subsys; enough for three breakthrough pain episodes/day. Subsys 1,200 mcg and Subsys 1,600 mcg strengths are supplied in packages of "30" (30 units of either 600 mcg or 800 mcg spray units). These packages of 30 only supply 15 doses since a patient must use two spray units of the lower strengths to achieve the higher, prescribed dose. The Express Scripts system does a conversion to ensure that these NDCs made up of 600 mcg and 800 mcg strengths accumulate correctly toward the above limit. That is, the patient is able to use three doses per day of 1,200 mcg or 1,600 mcg when these strengths are prescribed. <sup>†</sup> Lazanda doses are: 100 mcg, 200 mcg, 300 mcg, 400 mcg, 600 mcg, or 800 mcg. The limit accommodates three daily breakthrough pain episodes using the 200 mcg dose (two 100 mcg sprays) or maximum 800 mcg dose (two 400 mcg sprays).

**EXCEPTIONS TO THE QUANTITY LIMITS LISTED ABOVE ARE COVERED AS MEDICALLY NECESSARY WHEN THE FOLLOWING CRITERIA ARE MET. ANY OTHER EXCEPTION IS CONSIDERED NOT MEDICALLY NECESSARY.**

#### **CRITERIA**

Approval of additional quantities of the transmucosal fentanyl products is recommended if the patient is using the product for **breakthrough cancer pain** AND meets one of the following criteria:

#### Fentanyl Lozenges (Actiq, generic)

1. If the patient requires a quantity greater than 90 units during the initial titration phase (first 30 days of therapy), approve a one-time override for the requested quantity, not to exceed 120 units in a 30-day period at retail or 360 units in a 90-day period at home delivery.

Note: An override is not recommended for more than 120 units in a 30-day period at retail or 360 units in a 90-day period at home delivery; labeling notes that if a patient experiences more than four breakthrough pain episodes per day, then the dose of the long-acting opioid should be readjusted.

2. If the patient is experiencing more than three breakthrough pain episodes per day, approve the requested quantity, not to exceed 120 units per 30 days at retail or 360 units per 90 days at home delivery.

Note: An override is not recommended for more than 120 units per 30 days at retail or 360 units per 90 days at home delivery; labeling notes that if a patient experiences more than four breakthrough pain episodes per day, then the dose of the long-acting opioid should be readjusted.

3. If the patient is taking a dose that does not correspond to a commercially-available dosage form, approve a quantity sufficient that allows treatment of up to four breakthrough pain episodes per day per 30 days at retail or per 90 days at home delivery.

Note: This total number of units includes all forms of transmucosal fentanyl being used.

4. For patients who are receiving a dose greater than 1,600 mcg per breakthrough pain episode, approve a quantity sufficient that allows treatment of up to four breakthrough pain episodes per day per 30 days at retail or per 90 days at home delivery.

Note: This total number of units includes all forms of transmucosal fentanyl being used.

#### Fentanyl Buccal Tablet (Fentora, generic)

1. If the patient requires a quantity greater than 90 units during the initial titration phase (first 30 days of therapy), approve a one-time override for the requested quantity, not to exceed 120 units in a 30-day period at retail or 360 units in a 90-day period at home delivery.

Note: An override is not recommended for more than 120 units in a 30-day period at retail or 360 units in a 90-day period at home delivery; labeling notes that if a patient experiences more than four breakthrough pain episodes per day, then the dose of the long-acting opioid should be readjusted.

2. If the patient is experiencing more than three breakthrough pain episodes per day, approve the requested quantity, not to exceed 120 units per 30 days at retail or 360 units per 90 days at home delivery.

Note: An override is not recommended for more than 120 units per 30 days at retail or 360 units per 90 days at home delivery; labeling notes that if a patient experiences more than four breakthrough pain episodes per day, then the dose of the long-acting opioid should be readjusted.

3. If the patient is taking a dose that does not correspond to a commercially-available dosage form, approve a quantity sufficient that allows treatment of up to four breakthrough pain episodes per day per 30 days at retail or per 90 days at home delivery.

Note: This total number of units includes all forms of transmucosal fentanyl being used.

4. If the patient is receiving a dose greater than 800 mcg per breakthrough pain episode, approve a quantity sufficient that allows treatment of up to four breakthrough pain episodes per day per 30 days at retail or per 90 days at home delivery.

Note: This total number of units includes all forms of transmucosal fentanyl being used.

#### Subsys

1. If the patient requires a quantity greater than 90 units during the initial titration phase (first 30 days of therapy), approve a one-time override for the requested quantity, not to exceed 120 units in a 30-day period at retail or 360 units in a 90-day period at home delivery.

Note: An override is not recommended for more than 120 units in a 30-day period at retail or 360 units in a 90-day period at home delivery; labeling notes that if a patient experiences more than four breakthrough pain episodes per day, then the dose of the long-acting opioid should be readjusted.

- 2.** If the patient is experiencing more than three breakthrough pain episodes per day, approve the requested quantity, not to exceed 120 units per 30 days at retail or 360 units per 90 days at home delivery.  
Note: An override is not recommended for more than 120 units per 30 days at retail or 360 units per 90 days at home delivery; labeling notes that if a patient experiences more than four breakthrough pain episodes per day, then the dose of the long-acting opioid should be readjusted.
- 3.** If the patient is taking a dose that does not correspond to a commercially-available dosage form, approve a quantity sufficient that allows treatment of up to four breakthrough pain episodes per day per 30 days at retail or per 90 days at home delivery.  
Note: This total number of units includes all forms of transmucosal fentanyl being used.
- 4.** If the patient is receiving a dose greater than 1,600 mcg per breakthrough pain episode, approve a quantity sufficient that allows treatment of up to four breakthrough pain episodes per day per 30 days at retail or per 90 days at home delivery.  
Note: This total number of units includes all forms of transmucosal fentanyl being used.

#### Lazanda

- 1.** If the patient requires a quantity greater than 23 bottles during the initial titration phase (first 30 days of therapy), approve a one-time override of 30 bottles in a 30-day period at retail or 76 bottles in a 90-day period at home delivery.  
Note: An override is not recommended for more than 30 bottles in a 30-day period at retail or 76 bottles in a 90-day period at home delivery; labeling notes that if a patient experiences more than four breakthrough pain episodes per day, then the dose of the long-acting opioid should be readjusted.
- 2.** If the patient is experiencing more than three breakthrough pain episodes per day, approve to the requested quantity, not to exceed 30 bottles per 30 days at retail or 90 bottles per 90 days at home delivery.  
Note: An override is not recommended for more than 30 bottles at retail or 90 bottles at home delivery since the package labeling for these transmucosal fentanyl products notes that if patients experience up to four breakthrough pain episodes per day, then the dose of long-acting opioid should be adjusted.
- 3.** If the patient is taking a dose that does not correspond to a commercially-available dosage form, approve, a quantity sufficient that allows treatment of up to four breakthrough pain episodes per day per 30 days at retail or per 90 days at home delivery.  
Note: This total number of units includes all forms of transmucosal fentanyl being used.

## REFERENCES

1. Actiq® transmucosal lozenge [prescribing information]. Parsippany, NJ: Teva; December 2023.
2. Fentora® buccal tablet [prescribing information]. Parsippany, NJ: Teva; December 2023.
3. Subsys® sublingual spray [prescribing information]. Northbrook, IL: West; March 2021.
4. Lazanda® nasal spray [prescribing information]. Northbrook, IL: West; March 2021.
5. Transmucosal Immediate-Release Fentanyl (TIRF) Medicines. U.S. Food and Drug Administration Web site. Available at: <https://www.fda.gov/drugs/information-drug-class/transmucosal-immediate-release-fentanyl-tirf-medicines#:~:text=%5BSeptember%2016%2C%202024%5D%20On,discontinued%20on%20September%2030%2C%202024..> Created September 19, 2024. Accessed on April 23, 2025.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	Policy was updated to reflect the existing quantity limits when a product is obtained via home delivery.  <b>Lazanda 300 mcg/100 mL spray:</b> Removed from the policy (obsolete for more than 3 years).  No criteria changes.	05/15/2023
Annual Revision	No criteria changes.	05/15/2024
Annual Revision	The Policy Statement was clarified to note that "one-time" approvals are provided for 30 days in duration.	05/02/2025

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.